Q-omics provides the consensus-scored EIF3JP1 profile across patient tissues and cancer cell-line models. EIF3JP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, EIF3JP1 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, EIF3JP1 RNA expression shows 5,439 significant mutation-linked associations, with the highest sampling consensus in UCEC. Together, these results highlight DLBC, PRAD, and UCEC as cancer lineages where EIF3JP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3JP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3JP1 survival associations across molecular data types. EIF3JP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3JP1 RNA expression–survival associations across cancer types. High EIF3JP1 expression shows unfavorable associations in DLBC, PAAD, THYM, READ, ACC and MESO. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for EIF3JP1 RNA expression.
This table summarizes EIF3JP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3JP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3JP1 shows higher tumor expression in PRAD and LUSC. The PRAD box plot shows higher EIF3JP1 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .037).
This table shows molecular features associated with EIF3JP1 in patient tissues and cancer cell lines. In patient samples, EIF3JP1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
